Physician profile
Jean-Pierre Mobasser
NPI 1144213703
$3,522,367.54
in general payments reported to CMS, 2019-2025
7 companies · $688K in 2025
The $688K reported for 2025 was more than what 99% of Neurological Surgery providers received nationally (typical 2025 total: $604).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $457K · 2020: $386K · 2021: $307K · 2022: $268K · 2023: $758K · 2024: $660K · 2025: $688K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $2.1M · Consulting Fee: $2,975 · Food and Beverage: $272 · Education: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $2,101,729.00 |
| Consulting Fee | $2,975.00 |
| Food and Beverage | $271.85 |
| Education | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,679,223.76 | 2021-2025 | Divergence Anterior Cervical Fusion System, Cd Horizon Spinal System, Pivox Oblique Lateral Spinal System |
| Medtronic USA, INC. | $842,967.62 | 2019-2020 | |
| Stryker Corporation | $87.70 | 2019 | |
| Depuy Synthes Sales INC. | $29.70 | 2020 | |
| Zimmer Biomet Holdings, INC. | $22.73 | 2023 | Ti Rapidflap Spindown |
| Csl Behring | $20.00 | 2024 | Kcentra |
| Ucb, INC. | $16.03 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jean-Pierre Mobasser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.